It depends on the standard you follow. As of September 2026, 908 Devices Inc. (MASS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 23.7% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 23.7% / 33% · Receivables / Mkt Cap (36m) 4.12% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 23.7% / 33.33% · Receivables / Mkt Cap (24m) 4.12% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 55.0% / 33.33% · Receivables / Avg Assets (4Q) 6.48% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 49.7% / 33.33% · (Cash+Recv) / Total Assets 58.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, 908 Devices Inc. (MASS) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. 908 Devices Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
908 Devices Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
908 Devices Inc. (NASDAQ: MASS) is a Healthcare company (Medical - Specialties) with a market capitalization of $390M. The Maz Rating grades it against the other companies in its sector.
908 Devices Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $9.39, 908 Devices Inc. trades at 5.8x sales and 2.5x book value. Over the last twelve months it generated about $67M of revenue and a net loss of $27M. It runs a gross margin of 50.8%, an operating margin of -43.0% and a net margin of -36.7%. It shows return on equity of -17.4%, return on invested capital of -16.0% and a free cash flow yield of 0.7%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 5.43. Over the past 52 weeks the share price ranged from $5.03 to $13.35, with a beta of 0.63.
908 Devices Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 7 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.